Lymphoma Trial, Recruiting NCT03494296 Sponsor: First Affiliated Hospital of Harbin Medical University Condition: Lymphoma
Back to Lymphoma

Lymphoma Trial, Recruiting

NCT03494296
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Your cancer has been confirmed through a lab test (tissue sample) to be a specific type called Diffuse Large B-Cell Lymphoma (DLBCL)
  • Your lymphoma has come back or stopped responding to previous treatment
  • You are 18 years of age or older
  • Your overall health and ability to care for yourself is significantly limited (confirm with trial site)
  • If you are a woman, you are not breastfeeding, not pregnant, and agree to avoid pregnancy during the study and for 12 months after; if you are a man, you agree to ensure your partner does not become pregnant during the study and for 12 months after
  • You have at least one measurable area of disease, such as a lymph node measuring 1.0 cm or larger, or a visible skin lesion that can be examined physically
  • You are willing and able to sign a consent form agreeing to take part in the study

Who may not be able to join:

  • Your lymphoma has spread into your bone marrow and makes up 25% or more of the cells there
  • Your liver or kidney function test results are severely abnormal (more than 3 times higher than the normal range)
  • You have an active infection that is not under control
  • You have a heart condition with noticeable symptoms or significant problems with how your heart is working
  • You currently have another type of cancer at the same time
  • You have a psychological or mental health condition that would prevent you from taking part in the study or from signing a consent form

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Shuye Wang, PhD, First Affiliated Hospital of Harbin Medical University

Phone: 0451-85552320

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
First Affiliated Hospital of Harbin Medical University
Registry
ClinicalTrials.gov
Start date
1 March 2018
Est. completion
31 December 2020

Where this trial is recruiting

🇨🇳 China

Primary endpoints

A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov